To mitigate potential confounding factors of other background therapies, the study was designed to enroll known chronic heart failure patients who had already been on stable doses of maximally tolerated GDMT before the commencement of SGLT-2 inhibitor treatment. Here, SLC5A2 is linked to congestive heart failure.